Anika Therapeutics (ANIK) Acquisitions (2020 - 2021)
Anika Therapeutics (ANIK) posted quarterly Acquisitions of $113000.0 for Q4 2021, down 84.77% year-over-year from $742000.0 in Q4 2020, and up 927.27% quarter-over-quarter from $11000.0 in Q3 2021.
Anika Therapeutics (ANIK) Acquisitions (2020 - 2021) Analysis & Trends
Anika Therapeutics (ANIK) has reported Acquisitions for 2 consecutive years, with $113000.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Acquisitions fell 84.77% year-over-year to $113000.0; the TTM figure through Sep 2022 stood at $113000.0 (down 89.77% YoY), while the FY2021 annual figure was $476000.0, down 99.5% from the prior year.
- Acquisitions advanced to $113000.0 in Q4 2021 per ANIK's latest filing, from $11000.0 in the prior quarter.
- Across five years, Acquisitions topped out at $93.0 million in Q1 2020 and bottomed at $2000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 113,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | 350,000.00 |
| Dec 31, 2020 | 742,000.00 |
| Jun 30, 2020 | 876,000.00 |
| Mar 31, 2020 | 92.98 Mn |